Comparison of the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome patients after percutaneous coronary intervention
- VernacularTitle:替格瑞洛集采中标药与原研药用于ACS患者PCI后的疗效与安全性比较
- Author:
Yang MIAO
1
;
Zhongru MENG
1
;
Wang QI
1
;
Dan ZHANG
1
;
Kangshi XU
2
;
Hongxia WANG
1
Author Information
1. Dept. of Pharmacy，Yancheng First Hospital Affiliated of Nanjing University Medical School/Yancheng No. 1 People’s Hospital，Jiangsu Yancheng 224000，China
2. Dept. of Cardiovascular Medicine，Yancheng First Hospital Affiliated of Nanjing University Medical School/Yancheng No. 1 People’s Hospital，Jiangsu Yancheng 224000，China
- Publication Type:Journal Article
- Keywords:
ticagrelor;
acute coronary syndrome;
percu-
- From:
China Pharmacy
2024;35(20):2522-2526
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome （ACS） patients one year after percutaneous coronary intervention （PCI）. METHODS Overall 420 ACS patients treated with PCI in our hospital from July 2021 to June 2023 were divided into centralized procurement group （156 cases） and original drug group （264 cases） according to the different varieties of ticagrelor. All patients were given Aspirin enteric-coated tablets 100 mg regularly， once a day； on this basis， patients in the centralized procurement group were given Ticagrelor tablets winning the bidding， while patients in the original drug group were given the original drug of Ticagrelor tablets. The dosage of Ticagrelor tablets taken by both groups of patients was 90 mg， twice a day， and the course of treatment was 12 months. The blood routine indicators were compared before treatment and one week after treatment， while the incidence of net adverse clinical events （NACE）， major adverse cardiovascular and cerebrovascular events （MACCE） and bleeding events， and the survival rate without MACCE and bleeding events during a one-year follow-up after PCI were also compared between two groups. RESULTS There were no statistically significant differences in blood routine indicators before treatment and one week after treatment， as well as the incidence of NACE， MACCE and bleeding events， survival rate without MACCE and bleeding events during a one-year follow-up after PCI between the two groups （P＞0.05）. CONCLUSIONS During a one-year follow-up after PCI， the efficacy and safety of the drug winning the bidding for centralized procurement of ticagrelor are comparable to the original drug.
